Abstract # 2323 15-year Biochemical Relapse-Free Survival and Overall Survival Following 125I Prostate Brachytherapy in Clinically Localized Prostate Cancer: Seattle Experience.

Presenter: John Sylvester

About the Presenter:
Dr. John Sylvester completed both his Medical Degree and specialty training in Radiation Oncology at UCLA. He is board certified in Radiation Oncology by the American Board of Radiology. He was awarded the American Cancer Society Fellowship during his year as chief resident at UCLA. In 1987, he began performing prostate brachytherapy with Drs. Blasko and Grimm and joined the Seattle team full time in 1988. He is a member of the American Brachytherapy Society (ABS), The American Society of Therapeutic Radiation Oncology (ASTRO), and the American College of Radiology. Over the past 2 decades Dr. Sylvester has performed over 3000 prostate brachytherapy procedures. He has developed, and assisted in the development, of several technical improvements in the procedure, including how to better visualize the urethra during the procedure and how to optimally utilize R.A.P.I.D. strand. He was the first physician in the U.S to use I125 Echo Seed, a more visible (on ultrasound) radioactive seed. He was the lead Seattle investigator in a gene therapy protocol for salvage of external beam radiation therapy failures. He initiated the image-guided radiation therapy (IGRT) approach used at the Swedish Cancer Institutes’ Radiation Oncology centers, for more precise Intensity Modulated Radiation Therapy (IMRT) for prostate cancer. He is the lead investigator in a randomized trial evaluating the new ThinStrand™ versus standard size seeds. He is the lead investigator in a multi-institutional protocol evaluating the quality of life outcomes of patients treated with EBRT plus a Cesium seed implant boost. Dr. Sylvester is also working in partnership with the lead Brachytherapists at MDAH and Princess Margaret Hospital on a new brachytherapy outcomes nomogram to replace the outdated and inaccurate nomogram that is in current use. He is the lead Seattle investigator in a Palladium dose de-escalation protocol for men with low risk prostate cancer. He has published numerous articles and medical textbook chapters on prostate brachytherapy and co-authored and edited The Prostate Cancer Treatment Book. The above work has led Dr. Sylvester to being called upon to present at national and international conferences on prostate cancer on a regular basis. Recently, he presented the 15-year Seattle results on radioactive seed implantation of the prostate, at the American Society of Clinical Oncology (ASCO) and the World Congress of Endourology, and the “modern” Seattle outcomes data and technique at the May 2009 ABS conference in Toronto. He is also one of the three clinicians who wrote the most recent ABS guidelines used by prostate cancer Brachytherapists world wide. Dr. Sylvester was Director of the Puget Sound Tumor Institute from 1991 through 2000. Dr. Sylvester co-founded the Seattle Prostate Institute with Dr. Grimm in 1997 and served as the Director of Education and Training for 8 years. Together with Drs. Grimm and Blasko he ran a monthly program which trained more physicians in permanent seed implantation of the prostate, than any other in the world. They also ran the highly regarded Annual Advanced Prostate Brachytherapy Conference, held in Seattle. Dr. Sylvester was the Director of the Seattle Prostate Institute from 2006-2008. He is the Chief Medical Officer of Proqura, an organization developed by the Seattle team, focused on improving the quality of permanent prostate brachytherapy throughout the world. Proqura has developed a network of over 70 high-quality brachytherapy centers worldwide, and has multiple publications in the medical literature to that regard. Dr. Sylvester is currently both the Medical Director and Director of Research at the Seattle Prostate Cancer Center.

Abstract:


E-mail a friend about this poster:
Enter email address: